Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
Reinhard Dummer(University Hospital of Zurich), Michael R. Migden(The University of Texas MD Anderson Cancer Center), Karl D. Lewis(University of Colorado Denver), Ragini R. Kudchadkar, Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Alexander D. Guminksi(The University of Sydney), Anne Lynn S. Chang(Stanford University), Ruth Plummer(National Health Service), Nicholas Squittieri(Otsuka (United States)), P. Combemale(Centre Léon Bérard), Luc Dirix(European Organisation for Research and Treatment of Cancer), Carmen Loquai(Johannes Gutenberg University Mainz), John T. Lear(Salford Royal Hospital), Martin Kaatz(SRH Wald-Klinikum Gera), Uwe Trefzer(Charité - Universitätsmedizin Berlin), H.‐J. Schulze(Siemens (Germany)), Alexander Stratigos(National and Kapodistrian University of Athens)
Cited by 197
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k